[Treatment of neuroendocrine tumors with radio-labeled somatostatin analogues].

Item request has been placed! ×
Item request cannot be made. ×
loading   Processing Request
Read More Add to Saved list
  • Additional Information
    • Source:
      Publisher: Aluna Publishing Country of Publication: Poland NLM ID: 9705467 Publication Model: Print Cited Medium: Print ISSN: 0043-5147 (Print) Linking ISSN: 00435147 NLM ISO Abbreviation: Wiad Lek Subsets: MEDLINE
    • Publication Information:
      Publication: Konstancin Jeziorna : Aluna Publishing
      Original Publication: Warszawa : Pánstwowy Zakład Wydawnictw Lekarskich, [1960-
    • Subject Terms:
      Neuroendocrine Tumors/*drug therapy ; Radioisotopes/*therapeutic use ; Somatostatin/*analogs & derivatives; Humans ; Radioisotopes/adverse effects ; Renal Insufficiency/chemically induced
    • Abstract:
      There is a steady increase in the number of neuroendocrine tumors. Although the knowledge about this tumors' biology is increasing, they are still diagnosed in advanced stadium, when surgical treatment is not an option. One of the treatment methods which are available in this group of patients is peptide receptor radionuclide therapy, which should be considered in selected patients. This treatment is usually well tolerated by patients, though severe adverse events may occur, such as myelosuppression or renal failure.
    • Contributed Indexing:
      Keywords: treatment; metastatic disease; neuroendocrine neoplasms; peptide receptor radionuclide therapy
    • Accession Number:
      0 (Radioisotopes)
      51110-01-1 (Somatostatin)
    • Publication Date:
      Date Created: 20190210 Date Completed: 20190607 Latest Revision: 20190607
    • Publication Date:
      20221213
    • Accession Number:
      30737938